Serina Therapeutics receives funding to advance SER-252 into clinical trial

Serina Therapeutics (SER) announced the closing of the second $5M tranche of its previously announced $10M equity financing with strategic shareholder JuvVentures. The transaction provides Serina with funding to continue advancing SER-252, enabled by its proprietary POZ Platform drug optimization technology, into a Phase 1 clinical trial in advanced Parkinson’s disease patients in the second half of 2025. The closing represented the second tranche of the $10M total financing announced on December 2, 2024. The financing reinforces Serina’s ability to advance SER-252 into first-in-human studies. At closing, Serina issued 500,000 shares of common stock at $10 per share, representing a 113% premium to the closing price on January 31, 2025. Additionally, Serina issued warrants to JuvVentures for up to 755,728 shares of common stock at an exercise price of $18.00 per share.